Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gadobutrol - Bayer HealthCare Pharmaceuticals

Next Previous
Drug Profile

Gadobutrol - Bayer HealthCare Pharmaceuticals

Alternative Names: BAY-864875; Gadavist; Gadobutrol injection for MRI of CNS - Bayer; Gadovist; Gadovist 1.0; Gd-DO3A-butriol; SHL 562

Latest Information Update: 23 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer Schering Pharma
  • Developer Bayer HealthCare Pharmaceuticals
  • Class Gadolinium-containing contrast agents; Organometallic compounds; Small molecules
  • Mechanism of Action Magnetic resonance imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer; Coronary artery disease; Vascular disorders
  • No development reported Brain cancer

Most Recent Events

  • 13 Mar 2026 GE Healthcare plans a phase II/III LUMINA trial for CNS disorders(Diagnosis) (IV, Injection) (NCT07472491)(CTIS2025-523862-25-00) in March 2026
  • 29 Nov 2022 No development reported - Phase-III for Coronary artery disease (Diagnosis) in Australia (IV)
  • 29 Nov 2022 No development reported - Phase-III for Coronary artery disease (Diagnosis) in Canada (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top